Generic Name and Formulations:
Butenafine HCl 1%; crm.
Indications for MENTAX:
Tinea versicolor, t. corporis, t. cruris, and interdigital t. pedis.
Apply to affected and immediately surrounding area. T. versicolor, corporis, cruris: Apply once daily for 2 wks. T. pedis: Apply twice daily for 1 wk, or once daily for 4 wks. Reevaluate if no improvement after therapy.
Avoid eyes, nose, mouth, mucous membranes. Do not occlude. Discontinue if irritation develops and confirm diagnosis. Sensitivity to allylamines. Pregnancy (Cat.B). Nursing mothers.
Burning/stinging, worsening of condition, other local irritation.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage